Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids

被引:6
作者
Baakhtari, Sadaf Asl [1 ]
McCombie, Andrew [2 ]
Huinink, Sebastiaan ten Bokkel [1 ,5 ]
Irving, Peter [7 ]
Siegel, Corey A. [8 ]
Mulder, Roger [3 ]
Mulder, Chris J. [5 ,6 ]
Gearry, Richard [1 ,4 ]
机构
[1] Univ Otago, Dept Med, Christchurch, New Zealand
[2] Christchurch Hosp, Dept Surg, POB 4345, Christchurch, New Zealand
[3] Christchurch Hosp, Dept Psychol Med, Christchurch, New Zealand
[4] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
[5] Vrije Univ Amsterdam Med Ctr, Dept Med, Amsterdam, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
[7] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London, England
[8] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03766 USA
关键词
Corticosteroids; Side effects; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; CROHNS-DISEASE; NATURAL-HISTORY; THERAPY; ARTICLE; INDEX;
D O I
10.1159/000478772
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: We aimed to investigate the factors that make inflammatory bowel disease (IBD) patients more or less likely to be willing to take corticosteroids. Methods: Respondents completed a questionnaire. The primary outcome was whether the respondents would or would not use corticosteroids again to treat their IBD. Three separate univariate and multivariate analyses were performed to examine which variables predicted willingness to take steroids, including specific side effects. Results: Four hundred fifty three respondents (321 with Crohn's disease, 115 with ulcerative colitis; mean age 40 years, 297 [66%] female) completed the questionnaire. Corticosteroid efficacy (OR 6.83, 95% CI 3.67-12.7), lack of previous negative side effects (OR 0.11, 95% CI 0.04-0.32), and positive side effects (OR 2.96, 95% CI 1.63-5.40) were associated with a willingness to use corticosteroids in the future. In multivariate analysis, weight gain (OR 0.53, 95% CI 0.29-0.98) and hallucinations (OR 0.28, CI 0.09-0.89) were associated with an unwillingness to use corticosteroids again, whereas increased energy (OR 2.30, 95% CI 1.20-4.42) was the only significant positive side effect in a multivariate model. Conclusions: Past experiences with corticosteroids influence whether patients will take corticosteroids again. Clinicians should enquire about side effects and positive psychological symptoms associated with corticosteroid use. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:33 / 39
页数:7
相关论文
共 50 条
  • [21] Opioid Use Associated With Higher Costs Among Patients With Inflammatory Bowel Disease
    Szigethy, Eva M.
    Murphy, Sean M.
    Ehrlich, Orna G.
    Heller, Caren A.
    Engel-Nitz, Nicole M.
    Meadows, Perry
    Allen, John, I
    CROHNS & COLITIS 360, 2021, 3 (02)
  • [22] Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients
    Navaneethan, Udayakumar
    Kochhar, Gursimran
    Phull, Hardeep
    Venkatesh, Preethi G. K.
    Remzi, Feza H.
    Kiran, Ravi P.
    Shen, Bo
    JOURNAL OF CROHNS & COLITIS, 2012, 6 (04) : 470 - 475
  • [23] Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study
    Thorn, Mari
    Rorsman, Fredrik
    Ronnblom, Anders
    Sangfelt, Per
    Wanders, Alkwin
    Eriksson, Britt-Marie
    Bondeson, Kare
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1075 - 1080
  • [24] Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study
    Al Rifai, Ahmad
    Prasad, Neeraj
    Shuttleworth, Elinor
    McBurney, Helen
    Pushpakom, Sudeep
    Robinson, Andrew
    Newman, William
    Campbell, Simon
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (02) : 153 - 158
  • [25] Effect of inflammatory bowel disease treatments on patients with diabetes mellitus
    Bower, Joshua Ashley Jack
    O'Flynn, Lauren
    Kakad, Rakhi
    Aldulaimi, David
    WORLD JOURNAL OF DIABETES, 2021, 12 (08) : 1248 - 1254
  • [26] Standards, perspectives and limits of the conservative therapy of inflammatory bowel disease
    Rogler, G
    Andus, T
    Scholmerich, J
    ZENTRALBLATT FUR CHIRURGIE, 1998, 123 (04): : 316 - 324
  • [27] Current status and future perspectives of leukocytapheresis for inflammatory bowel disease
    Fukunaga, Ken
    Matsumoto, Takayuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (06) : 997 - 1003
  • [28] Probiotic and Prebiotic Use in Patients with Inflammatory Bowel Disease: A Case-Control Study
    Hedin, Charlotte R. H.
    Mullard, Miriam
    Sharratt, Elizabeth
    Jansen, Clare
    Sanderson, Jeremy D.
    Shirlaw, Penelope
    Howe, Leslie C.
    Djemal, Serpil
    Stagg, Andrew J.
    Lindsay, James O.
    Whelan, Kevin
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (12) : 2099 - 2108
  • [29] Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study
    Lo, Bobby
    Julsgaard, Mette
    Vester-Andersen, Marianne Kajbaek
    Vind, Ida
    Burisch, Johan
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (10) : 1130 - 1136
  • [30] Internet use by patients in an inflammatory bowel disease specialty clinic
    Cima, Robert R.
    Anderson, Kari J.
    Larson, David W.
    Dozois, Eric J.
    Hasson, Imran
    Sandborn, William J.
    Loftus, Edward V.
    Pemberton, John H.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (10) : 1266 - 1270